Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Hansa Biopharma AB at UBS Global Healthcare Conference Transcript

May 20, 2019 / 02:00PM GMT
Release Date Price: kr173.7 (-1.75%)
Mallet Njonkem

Good morning, everyone, and welcome to the 2019 UBS Global Healthcare Conference. My name is Mallet Njonkem, and I'm happy to be your host this session. Now please join me in welcoming our next presenter, Mr. Emanuel Bjorn, Vice President of Global Business Development at Hansa Biopharma.

A breakout session will follow immediately after this presentation in the Julliard room. Thank you, and enjoy.

Emanuel BjÃ;rne;publ;VP of Global Business Development
Hansa Biopharma AB

¶ - ()-

Thank you very much. My name is Emanuel Bjorn, and I'm Vice President, Global Business Development of Hansa Biopharma. We are based in Sweden. We have operations in the U.S. and in Europe. Let's see here.

Please take a look at our forward-looking statements slide here. And we are a clinical stage -- late clinical-stage biopharma development company. We're focused on acute autoimmune diseases and transplant rejection. And quite recently, media here in the U.S. and in Europe have noticed our clinical results. For

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot